EYPT Q1 2024 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+52.1% YoY

Gross Profit

$11M93.5% margin

Operating Income

-$33M-285.2% margin

Net Income

-$29M-250.6% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

-16.7%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$32M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$329M

Total Liabilities

$79M

Stockholders' Equity

$250M

Cash & Equivalents

$271M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$8M	+52.1%
Gross Profit	$11M	$7M	+55.1%
Operating Income	-$33M	-$22M	-54.6%
Net Income	-$29M	-$21M	-38.4%